

- 7 -

WE CLAIM

1. A therapeutic composition, comprising a non-toxic transglutaminase inhibitor having a free amino group or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier or diluent.
2. A composition according to claim 1, wherein the inhibitor is a primary amine.
3. A composition according to claim 2, wherein the amine is a polyamine.
4. A composition according to claim 3, wherein the amine is aliphatic.
5. A composition according to claim 4, wherein the amine is a C1-5 alkyl amine.
6. A composition according to claim 5, wherein the amine is putrescine.
7. A composition according to claim 6, wherein the carrier is a eutectic cream or ointment.
8. A method of treating hypertrophic scar tissue, comprising applying to the scar tissue an effective amount of a non-toxic transglutaminase inhibitor having a free amino group or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier or diluent.
- 2.9. A method according to claim 8, wherein the effective amount is 25 to 100 mM.
- 3.10. A method according to claim 9, wherein the effective amount is about 50 mM.
11. A method according to claim 10, wherein the inhibitor is a

- 8 -

*Ad¹
B²*
primary amine.

5 ~~12.~~ A method according to claim ~~11~~, wherein the amine is a polyamine.

6 ~~13.~~ A method according to claim ~~12~~, wherein the amine is a C1-5 alkyl amine.

7 ~~14.~~ A method according to claim ~~13~~, wherein the amine is putrescine.

8 ~~15.~~ A method according to claim ~~14~~, wherein the carrier is a eutectic cream or ointment.

*Ad¹
B³*

C⁷

Am 10
SUBSTITUTE SHEET